The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > SUGEN, Inc.

SUGEN, Inc.
 PROFILE
SUGEN is surging forward with its drug research. A subsidiary of Pharmacia, it develops drugs that target cellular signal transduction pathways; variations in these pathways are present in cancer, diabetes, and other disorders. SUGEN's drugs are intended to signal molecules that function as enzymatic switches to turn specific pathways on and off. Its lead drug candidate is an antiangiogenesis drug that prevents new blood vessels from forming around a tumor, which deprives the cancer of its blood supply. The compound, SU5416, targets colorectal cancer, AIDS-related Kaposi's sarcoma, and solid tumors. In addition to cancer, SUGEN targets inflammatory, autoimmune, and cardiovascular conditions and other diseases.

 COMPETITION
ImClone Systems Incorporated (IMCL)
Signal Research Division (dossier)
Transkaryotic Therapies, Inc. (TKTX)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1998 Sales (mil.): 14.90
1-Yr. Sales Growth: 148.3%
Employees: 239
Revenue per employee: $62,343.10

 CONTACT INFO
230 E. Grand Ave.
South San Francisco, CA 94080
US
Phone: 650-837-3300
Fax: 650-553-8301
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001